Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making VFA Part of Standard Clinical DXA Assessment for Osteoporosis Care: Recommendations From the International Working Group on DXA Best Practices.

Mayo Clinic proceedings·2025
Same author

Updated practice guideline for dual-energy X-ray absorptiometry (DXA).

European journal of nuclear medicine and molecular imaging·2024
Same author

Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices.

Mayo Clinic proceedings·2024
Same author

MANAGEMENT OF HYPERPARATHYROIDISM IN KIDNEY TRANSPLANTATION CANDIDATES: A NEED FOR CONSENSUS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2019
Same author

Sporadic primary hyperparathyroidism: medical and surgical updates.

Expert review of endocrinology & metabolism·2019
Same author

Use of bone turnover markers in the management of osteoporosis.

Current opinion in endocrinology, diabetes, and obesity·2018
Same journal

EDITORIAL INTRODUCTION.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Exploring the role of parathyroid hormone in sarcopenia: A review.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Normocalcemic primary hyperparathyroidism: an update on diagnostic and management challenges.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Prediabetes before pregnancy: implications for risk stratification and research.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Secondary hyperparathyroidism in chronic kidney disease: update on pathophysiology and new treatment targets.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence.

Current opinion in endocrinology, diabetes, and obesity·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Primary hyperparathyroidism: an update.

Zeina Habib1, Pauline Camacho

  • 1Division of Endocrinology and Metabolism, Loyola University Medical Center, Maywood, Illinois, USA.

Current Opinion in Endocrinology, Diabetes, and Obesity
|October 5, 2010
PubMed
Summary
This summary is machine-generated.

Primary hyperparathyroidism (PHPT) is a complex endocrine disorder. Current research highlights its cardiovascular and neuropsychiatric effects, with surgery remaining the primary treatment for eligible patients.

More Related Videos

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

Procurement of Parathyroid Glands from Living Donor Pigs and Ex Vivo Identification
08:07

Procurement of Parathyroid Glands from Living Donor Pigs and Ex Vivo Identification

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jun 8, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

Procurement of Parathyroid Glands from Living Donor Pigs and Ex Vivo Identification
08:07

Procurement of Parathyroid Glands from Living Donor Pigs and Ex Vivo Identification

Published on: August 1, 2025

Area of Science:

  • Endocrinology
  • Metabolic Bone Disease

Background:

  • Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by excessive parathyroid hormone secretion.
  • Emerging evidence links even asymptomatic PHPT to cardiovascular and neuropsychiatric issues.

Purpose of the Study:

  • To provide an updated perspective on the current phenotype of PHPT.
  • To review evolving therapeutic options and surgical indications for PHPT.

Main Methods:

  • Review of current literature on PHPT pathogenesis, clinical manifestations, and treatment.
  • Analysis of recent revisions in surgical indications for asymptomatic PHPT.

Main Results:

  • The exact pathogenesis of PHPT is still under investigation, with potential roles for genetic factors and vitamin D deficiency.
  • Asymptomatic PHPT is increasingly associated with cardiovascular and neuropsychiatric dysfunction, though clinical significance and reversibility require further study.
  • Medical therapies like bisphosphonates and calcimimetics show promise, but parathyroidectomy remains the only curative treatment.

Conclusions:

  • Parathyroidectomy is the recommended treatment for symptomatic PHPT and selected asymptomatic cases based on specific criteria.
  • Further research is necessary to ascertain the benefits of parathyroidectomy for patients with significant cardiovascular and neuropsychiatric symptoms.